News Center

Latest Press Releases

Summary Toggle Ironwood Pharmaceuticals Presenting IW-3718 and Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting

Oct 8, 2018

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 8, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the presentation of clinical data for IW-3718 and linaclotide from the company and its collaborators during the American College of Gastroenterology
Read more

PDF Version
Summary Toggle Ironwood Pharmaceuticals Announces FDA Fast Track Designation for Praliciguat for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Sep 13, 2018

– Praliciguat Phase II trial in HFpEF continues to enroll patients with topline data expected in the second half of 2019 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 13, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today announced that the U.S.

Read more

PDF Version
Summary Toggle Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

Aug 28, 2018

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 28, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in September: 2018 Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 1:55 p.m.

Read more

PDF Version
Summary Toggle Approval of Linzess® Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation

Aug 21, 2018

TOKYO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 21, 2018-- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., “Astellas” ) and Ironwood Pharmaceuticals, Inc (Nasdaq: IRWD , “Ironwood”) today announced that approval has been obtained in Japan for the guanylate cyclase-C

Read more

PDF Version

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter

News Center

Latest Press Releases

Latest Tweets